Publication
Ireland
On 31 October 2023, the Screening of Third Country Transactions Act 2023 (the “Act”), which establishes a new foreign direct investment ("FDI") screening regime in Ireland, was enacted.
Canada | Publication | July 2022
Our 2022 Guide to Canada’s Pharmaceutical Intellectual Property Regime is a convenient all-in-one reference to the important legal and regulatory regimes governing pharmaceuticals in Canada.
The Guide provides a detailed review of the key regimes, including:
We are honoured that the Guide includes a Foreword by our partner, The Right Honourable Brian Mulroney. During his tenure as the 18th Prime Minister of Canada, Mr. Mulroney championed a series of significant legislative reforms to improve protections for pharmaceuticals that continue to operate today. The COVID-19 pandemic has highlighted the importance of fostering investment in research, development and manufacturing by the innovative pharmaceutical industry in Canada. Norton Rose Fulbright’s pharmaceuticals and life sciences team understands the innovative pharmaceutical industry and will continue to work with innovators to defend their rights and maintain the benefits they bring to all Canadians.
We hope this Guide will assist in navigating the complex challenges of this rapidly evolving field.
Publication
On 31 October 2023, the Screening of Third Country Transactions Act 2023 (the “Act”), which establishes a new foreign direct investment ("FDI") screening regime in Ireland, was enacted.
Publication
The European Commission (EC) is contemplating a revision of the procedural framework for antitrust investigations that is laid down in Regulation 1/2003 and Regulation 773/2004 (together, the “Regulations”).
Publication
The concept of “without prejudice” (WP) is well-established in common law jurisdictions and protects statements, offers, or admissions made during settlement negotiations from being used as evidence in court if the negotiations fail.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023